Preferred Label : CDK2/4/6 Inhibitor PF-07224826;
NCIt definition : An orally bioavailable small molecule inhibitor of cyclin-dependent kinase (CDK) types
2 (CDK2), 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral
administration, CDK2/4/6 inhibitor PF-07224826 selectively targets and inhibits CDK2,
CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early
in the G1 phase and prevents CDK-mediated G1-S-phase transition. This leads to cell
cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation.
CDKs are serine/threonine kinases that are important regulators of cell cycle progression
and cellular proliferation and are upregulated in many tumor cell types.;
Molecule name : PF 07224826; PF-07224826;
Origin ID : C200815;
concept_is_in_subset
- has_target
